While they both promote insulin release, the GLP-1 receptor reduces the release of another hormone made by the pancreas called glucagon, which balances the effects of insulin on blood sugar, while the GIP receptor promotes glucagon release
The consistency of results stood out to investigators
Indeed, preclinical studies have shown that both agonism and antagonism of GIP receptors can reduce hyperglycaemia and body weight [49, 52]
This article explains how they work, who can use them, their benefits, side effects, and how they compare with other diabetes treatments
what changes is the total
This is the core of Nooms GLP-1 Rx Program, which is designed to minimize side effects through our SmartDose protocol while maximizing outcomes with integrated support for healthy habits